A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

Schizophrenia Research
L Fredrik JarskogMargaret A Peykamian

Abstract

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

References

Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Feb 13, 2001·Progress in Neurobiology·R E BrownH L Haas
Dec 16, 2011·Trends in Cognitive Sciences·Deanna M Barch, Alan Ceaser
Oct 29, 2013·Bioorganic & Medicinal Chemistry Letters·David M WilsonAndrew D Medhurst
Nov 26, 2013·Bioorganic & Medicinal Chemistry Letters·David M WilsonAndrew D Medhurst

❮ Previous
Next ❯

Citations

Aug 19, 2015·Neuropharmacology·Maximiliano Rapanelli, Christopher Pittenger
Apr 12, 2017·CNS Drugs·Joshua T Kantrowitz
May 20, 2017·Expert Opinion on Drug Discovery·Mitsuyuki MatsumotoKatsunori Tajinda
Jan 12, 2017·Evidence-based Mental Health·Sven Trelle
Jan 18, 2018·Expert Opinion on Therapeutic Patents·Dorota Łażewska, Katarzyna Kieć-Kononowicz
Apr 5, 2016·Annals of the New York Academy of Sciences·Annette B Brühl, Barbara J Sahakian
Mar 14, 2019·Current Opinion in Neurology·David KremerPatrick Küry
Aug 4, 2020·British Journal of Pharmacology·Takeo YoshikawaKazuhiko Yanai
Oct 3, 2018·Multiple Sclerosis : Clinical and Laboratory Research·David KremerRanjan Dutta
Jun 30, 2019·Current Treatment Options in Neurology·Lindsey WooliscroftDennis Bourdette
Aug 3, 2021·Frontiers in Neuroscience·Elliott Carthy, Tommas Ellender

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here